We thus posit that the PG2-induced downregulation of IL-6 and IL-10 suggests that, dependent on the TME and cytokine landscape, PG2 exhibits not only a tumoricidal but also tumoristatic effects on NSCLC cells. This evidence concerns the gene IL6 and non-small cell lung carcinoma.